President, Chief Executive Officer & Director
Executive VP & CFO
Carlo de Notaristefani
Executive Vice President of Global Operations
Teva founded in the year 1901. The company has been operational for almost 118 years now. The founders of the company were Yitschak Elstein, Dr Gunther Friedlander, Chaim Salomon and Moshe Levin. The former name of the company was Salomon, Levin, and Elstein Limited. The company was built with an investment of just 4,900-pound sterling, which had come from the family's own capital and partly from other loans from other German immigrants as well. Due to capital shortage leads to the joining of the banker Dr Alfred Feuchtwanger as a partner in the company, who received 33% of the shares in return for his investment as well. In the year 1951, Dr Feuchtwanger had initiated an IPO or Initial Public Offering, in order to raise capital and make the company a limited public entity as well.
During WWII and until the termination of the British Mandatory Palestine regime, the company had exported its medical products to all the Arab countries. In the year 1941, Dr Friedländer had presented the company products in an exhibition held in Cairo, Egypt, as well. The exhibition was then sponsored by the general agent and also the sole distributor of medicine in Egypt and Sudan, Syria and even Lebanon as well. Later onwards, the company had exported its products to the USA, Russia and even health institutes in Denmark, Persia, Burma, etcetera. In the year 1980, the company continued to follow its vision of becoming one of the world's biggest pharmaceutical companies by also acquiring Ikapharm as well - which was then Israel's second-largest drug manufacturer. Later in the year 1982, Teva was granted approval by the USA Food and Drug Administration for its Kfar Saba manufacturing plant, which an essential milestone for marketing pharmaceuticals in the USA. As of the year 1980, Teva had acquired Plantex. In the year 2000, the company had acquired Canada-based company, Novopharm. Then in the year 2003, the company had announced its intentions to acquire Sicor for $3.4 billion. As of the year 2005, the company had opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim - which is a technology park in Jerusalem. The plant had received FDA approval in the year 2007. The company had entered the Japanese market in the year 2005, and also in the year 2008 and established a generics joint venture with Kowa. In the year 2006, the company said it had completed the acquisition of IVAX Corporation for almost $7.4 billion. By the year 2010, the company had said that it planned to acquire German generic Ratiopharm for $5 billion. The deal was completed in the year 2010 as well. By the year 2011, the company had announced it would purchase Cephalon for $6.8 billion, in order to help expand its presence in the proprietary pharmaceuticals sector as well. In the year 2014, the company had acquired NuPathe, for almost $144 million. Finally, as of the year 2015, Allergan had agreed to sell its generic drug business to Teva for $40.5 billion. The headquarters of the company is based in Basel Street 5. The name of the place is Petah Tikva, while the country name is Israel.
Teva is a company based in Israel which focuses on the manufacturing and selling of various kinds of pharmaceutical drugs and products, all over the world. The current CEO and president of the company are Kare Schultz. As of the year 2018, the total revenue generated by the company is more than $18.9 billion. Also, the number of employees working in the company is more than 42,500, as of the year 2018.
The primary services provided by the company include allowing customers and clients to obtain various kinds of pharmaceutical drugs and products, that are developed, marketed and sold by the company itself. The company is the largest generic drug manufacturer in the world. The company mainly specialises in generic drugs along with pharmaceutical ingredients as well.
Please log in again. The login page will open in a new window. After logging in you can close it and return to this page.